- Oct 17, 2011
- 42,338
- 45,448
- Country
- United States
- Faith
- Atheist
- Marital Status
- Legal Union (Other)
Prasad, an oncologist and a professor of epidemiology, biostatistics and medicine at the University of California, San Francisco, had previously criticized the FDA.
He was a fierce critic of US Covid-19 vaccine and mask mandates and, in the second Trump administration, he was controversially appointed as the director of the FDA’s center for biologics evaluation and research in May.
The government gave no details about the reason for his departure but he had fierce critics on both sides of the political aisle and the Washington Post reported, citing unnamed sources, that he had been ousted amid protests by conservative voices, with no response from Prasad to requests for comment.
[joking about having a Donald Trump 'voodoo doll' may have contributed to his exit, according to reports in the US media.]
His exit came after a number of unusual regulatory actions, including those taken recently by the agency on Sarepta Therapeutics’ gene therapy, Elevidys.
[And declining to approve some other drugs and downplaying COVID vaccination.]
The regulator’s decisions under Prasad raised concerns that he was anti-patient choice, Jefferies analyst Roger Song said, adding that investors will see his departure as a positive for gene therapy and vaccine makers.
He was a fierce critic of US Covid-19 vaccine and mask mandates and, in the second Trump administration, he was controversially appointed as the director of the FDA’s center for biologics evaluation and research in May.
The government gave no details about the reason for his departure but he had fierce critics on both sides of the political aisle and the Washington Post reported, citing unnamed sources, that he had been ousted amid protests by conservative voices, with no response from Prasad to requests for comment.
[joking about having a Donald Trump 'voodoo doll' may have contributed to his exit, according to reports in the US media.]
His exit came after a number of unusual regulatory actions, including those taken recently by the agency on Sarepta Therapeutics’ gene therapy, Elevidys.
[And declining to approve some other drugs and downplaying COVID vaccination.]
The regulator’s decisions under Prasad raised concerns that he was anti-patient choice, Jefferies analyst Roger Song said, adding that investors will see his departure as a positive for gene therapy and vaccine makers.
